NPY5R

Across TCGA pan-cancer cohorts, NPY5R Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NPY5R data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPY5R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPY5R expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

LIHC, PAAD, and UCEC are the cancer types where NPY5R Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.145	0.786	<.001	28	view →
PAAD	OS	Median	All	0.110	0.640	<.001	24	view →
UCEC	DFS	Median	All	0.936	0.617	.011	16	view →
LUSC	DFS	Median	All	1.000	0.651	.017	7	view →
PRAD	OS	Median	All	0.693	0.990	<.001	6	view →
LUAD	DFS	Median	All	0.925	0.656	.031	5	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NPY5R–LIHC (OS)

Open the LIHC breakdown →